Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake

[1]  M. Schlumberger.  Tumeurs de la thyroïde , 1997 .

[2]  J. Hanke,et al.  Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Q. Duh,et al.  Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo. , 1996, The Journal of clinical endocrinology and metabolism.

[4]  E. Baudin,et al.  Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. , 1996, The Journal of clinical endocrinology and metabolism.

[5]  F. Jamar,et al.  Indium-111-pentetreotide uptake in endocrine tumors and lymphoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  C. Ingvar,et al.  Dynamic indium-111-pentetreotide scintigraphy in breast cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  Z. Kusic,et al.  Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  S. Lamberts,et al.  Somatostatin receptor manipulation. , 1996, Digestion.

[9]  H. van Toor,et al.  Somatostatin receptor scintigraphy in non-medullary thyroid cancer. , 1996, Digestion.

[10]  R. Valkema,et al.  Somatostatin receptor: scintigraphy and radionuclide therapy. , 1996, Digestion.

[11]  D. A. Meier,et al.  Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  L. Edenbrandt,et al.  Dynamic Octreotide Scintigraphy in Neuroendocrine Tumours , 1995, Acta radiologica.

[13]  B. Caillou,et al.  Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  T. Visser,et al.  Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  G. Krejs,et al.  Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  T. Visser,et al.  Radiotherapy with a Radiolabeled Somatostatin Analogue, [111In‐DTPA‐d‐Phe1]‐Octreotide , 1994 .

[17]  T. Miyamoto,et al.  Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. , 1994, The Journal of clinical endocrinology and metabolism.

[18]  K. Ain,et al.  Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. , 1994, The Journal of clinical endocrinology and metabolism.

[19]  W. Oyen,et al.  Is somatostatin receptor scintigraphy suited to detection of acute infectious disease? , 1994, Nuclear medicine communications.

[20]  J. Jeekel,et al.  Somatostatin-receptor scintigraphy in primary breast cancer , 1994, The Lancet.

[21]  J. Laissue,et al.  High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor‐host interaction? , 1994, International journal of cancer.

[22]  A. Avraham,et al.  Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  P. Flamen,et al.  Imaging of renal cell cancer with radiolabeled octreotide , 1993, Nuclear medicine communications.

[24]  B. van Eck-Smit,et al.  Comparison of serum thyroglobulin, 131I and 201Tl scintigraphy in the postoperative follow-up of differentiated thyroid cancer. , 1993, Nuclear medicine communications.

[25]  E. Krenning,et al.  Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implications , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  M. Sheppard,et al.  Serum thyroglobulin measurements in thyroid cancer: evaluation of‘false’ positive results , 1991, Clinical endocrinology.

[27]  A. Bockisch,et al.  [A comparison of 201Tl and 99mTc-MIBI in the follow-up of differentiated thyroid carcinomas]. , 1991, Nuklearmedizin. Nuclear medicine.

[28]  S. Hanau,et al.  Somatostatin reduces 3H-thymidine incorporation and c-myc, but not thyroglobulin ribonucleic acid levels in human thyroid follicular cells in vitro. , 1991, The Journal of clinical endocrinology and metabolism.

[29]  G. Braunstein,et al.  Thallium-201 scintigraphy in differentiated thyroid cancer: comparison with radioiodine scintigraphy and serum thyroglobulin determinations. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  L. Kvols,et al.  In vitro and in vivo detection of somatostatin receptors in human malignant tissues. , 1991, Acta oncologica.

[31]  T. Visser,et al.  In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. , 1991, Life sciences.

[32]  T. Sumida,et al.  Somatostatin receptors on human lymphocytes and leukaemia cells. , 1990, Immunology.

[33]  G. Ronga,et al.  Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma? , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  E. Krenning,et al.  Somatostatin-receptor imaging in the localization of endocrine tumors. , 1990, The New England journal of medicine.

[35]  J. Charboneau,et al.  Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. , 1990, Cancer research.

[36]  N. Kimura,et al.  Characterization of 17-beta-estradiol-dependent and -independent somatostatin receptor subtypes in rat anterior pituitary. , 1989, The Journal of biological chemistry.

[37]  E. P. Krenning,et al.  LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN , 1989, The Lancet.

[38]  N. Mahy,et al.  Characteristics of somatostatin desensitization in the pituitary tumor cell line AtT-20. , 1988, The Journal of pharmacology and experimental therapeutics.

[39]  G. Manciet,et al.  Thallium-201 imaging in the follow-up of differentiated thyroid carcinoma. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  H. Müller-Gärtner,et al.  Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer , 1988, Cancer.

[41]  D. Casara,et al.  Critical evaluation of serum thyroglobulin (Tg) levels during thyroid hormone suppression therapy versus Tg levels after hormone withdrawal and total body scan: Results in 291 patients with thyroid cancer , 1986, European Journal of Nuclear Medicine.

[42]  D. Berman,et al.  Correlation of thyroglobulin measurements and radioiodine scans in the follow‐up of patients with differentiated thyroid cancer , 1985, Cancer.

[43]  D. Donohoe,et al.  Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow‐up of differentiated thyroid carcinoma , 1984, Cancer.

[44]  A. Schonbrunn,et al.  Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. , 1982, Endocrinology.

[45]  N. Samaan,et al.  Critical evaluation of serum thyroglobulin levels and I-131 scans in post-therapy patients with differentiated thyroid carcinoma: concise communication. , 1982, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  H. Bikker,et al.  Serum thyroglobulin levels: the physiological decrease in infancy and the absence in athyroidism. , 1981, The Journal of clinical endocrinology and metabolism.

[47]  M. Ashcraft,et al.  The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer. , 1981, The American journal of medicine.

[48]  M. Schlumberger,et al.  Circulating thyroglobulin and thyroid hormones in patients with metastases of differentiated thyroid carcinoma: relationship to serum thyrotropin levels. , 1980, The Journal of clinical endocrinology and metabolism.

[49]  B. Ahrén,et al.  Somatostatin inhibits thyroid hormone secretion induced by exogenous TSH in man. , 1978, The Journal of clinical endocrinology and metabolism.

[50]  uller,et al.  Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas. , 1975, The Journal of clinical investigation.